Marlborough, MA, United States of America

Christoph Wolfgang Zapf

This inventor holds 25 USPTO granted patents and 13 published patent applications, plus 6 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Pfizer Corporation, Nurix Therapeutics, Inc., Cystic Fibrosis Foundation. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christoph Wolfgang Zapf. Retrieved from https://idiyas.com/inventor/christoph-wolfgang-zapf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 25 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 12.0

ph-index = 6

Forward Citations = 137(Granted Patents)


Location History:

  • Oakland, CA (US) (2019 - 2020)
  • Marlborough, MA (US) (2016 - 2023)
  • San Francisco, CA (US) (2018 - 2024)

Company Filing History:


Years Active: 2016-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Cbl-B Inhibition
CFTR Potentiators
Bruton's Tyrosine Kinase
Pyrrolopyrimidines
Bicyclic Compounds
Heteroaryl Derivatives
Piperidine Compounds
Triazole Compounds
Aryl Compounds
Substituted Compounds
Cyclobutyl Compounds
IRAK4 Modulators
25 patents (USPTO):Explore Patents

Title: The Innovative Journey of Christoph Wolfgang Zapf

Introduction:

Christoph Wolfgang Zapf, a prolific inventor based in Marlborough, MA (US), has made significant contributions to the world of pharmaceuticals and immunology through his remarkable inventions. With an impressive portfolio of 18 patents, Zapf is renowned for his groundbreaking research and advancements in the field of compound synthesis and immune system modulation.

Latest Patents:

1. Bicyclic-fused heteroaryl or aryl compounds: Zapf's latest patent showcases compounds with a unique structure aimed at pharmaceutical applications, including potential treatments and synthesis methods.

2. Cyano cyclobutyl compounds for CBL-B inhibition: This patent reveals compounds designed to inhibit the E3 enzyme Cbl-b, offering innovative solutions for immune system modulation and cancer treatment.

Career Highlights:

Zapf has left his mark on esteemed organizations such as Pfizer Corporation and Cystic Fibrosis Foundation Therapeutics, Inc., where his expertise and inventive spirit have led to transformative advancements in the field of medicine. His dedication to research and development has earned him a reputation as a trailblazer in the industry.

Collaborations:

Throughout his career, Zapf has collaborated with industry stalwarts like Joseph Walter Strohbach and John Paul Mathias, fostering a culture of innovation and excellence. Together, they have worked on cutting-edge projects that have paved the way for novel treatments and therapies.

Conclusion:

In conclusion, Christoph Wolfgang Zapf stands as a visionary inventor whose ingenuity has propelled the realms of pharmaceuticals and immunology to new heights. His relentless pursuit of innovation, coupled with his collaborative efforts, underscores his commitment to making a lasting impact on the world of medicine. As Zapf continues to push boundaries and explore new frontiers, his legacy as a pioneering inventor is sure to endure for years to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…